A phase 1, placebo-controlled, double-blind study of the safety and immunogenicity of two injections of MVA3000 modified vaccinia ankara (MVA) smallpox vaccine in vaccinia naive adult subjects with a history of atopic dermatitis (AD)
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2014
At a glance
- Drugs MVA 3000 (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 17 Jan 2014 Planned End Date changed from 1 Sep 2007 to 1 Jan 2007 as per ClinicalTrials.gov record.
- 07 Jan 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
- 22 Jun 2007 New trial record.